The upcoming earnings report for Summit Therapeutics is crucial as it will reveal whether the company meets or exceeds the EPS estimate of -0.07. However, the stock price may be more influenced by the company's guidance for future growth, as historical data shows that even when EPS estimates are beaten, the stock price can still decline. This suggests that investors are more focused on the company's future outlook.